Yukiya Narita

17PUBLICATIONS
87CO-AUTHORS
Cellular immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiology not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 19, 2026
Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report.

|Jun 01, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

|Apr 13, 2026
Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Kazunori Honda, Kazuhiro Shimomura, Hiroya Taniguchi

|Mar 12, 2026
Regorafenib in refractory gastric cancer: modest median, meaningful milestone.

Yukiya Narita, Kei Muro

|Mar 06, 2026
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.

Yukiya Narita, Hisato Kawakami, Koki Nakanishi

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

Pageof 3

Frequent Collaborators

9 joint publications

Kei Muro

3 joint publications

Taro Mizuno

3 joint publications

Yasunobu Ishizuka

3 joint publications

Hiroki Hara